Menu
Search
|

Menu

Close
X

Ipsen SA IPN.PA (Paris Stock Exchange)

122.00 EUR
-1.85 (-1.49%)
As of Feb 23
chart
Previous Close 123.85
Open 123.85
Volume 99,664
3m Avg Volume 122,390
Today’s High 123.85
Today’s Low 121.70
52 Week High 129.85
52 Week Low 81.73
Shares Outstanding (mil) 83.66
Market Capitalization (mil) 9,633.51
Forward P/E 44.34
Dividend (Yield %) 0.85 ( 0.74 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.92 Mean rating from 13 analysts

KEY STATS

Revenue (mm, EUR)
FY17
2,012
FY16
1,671
FY15
1,520
EPS (EUR)
FY17
3.232
FY16
2.730
FY15
2.294
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
44.34
32.90
Price to Sales (TTM)
vs sector
5.25
5.77
Price to Book (MRQ)
vs sector
6.80
5.41
Price to Cash Flow (TTM)
vs sector
33.48
23.42
Total Debt to Equity (MRQ)
vs sector
63.13
16.52
LT Debt to Equity (MRQ)
vs sector
31.68
12.22
Return on Investment (TTM)
vs sector
11.19
14.43
Return on Equity (TTM)
vs sector
16.34
16.13

EXECUTIVE LEADERSHIP

Marc de Garidel
Non-Executive Chairman of the Board, Chief Executive Officer, Since 2010
Salary: €81,989.00
Bonus: --
James Levine
President, Since 2017
Salary: --
Bonus: --
David Meek
Chief Executive Officer, Since
Salary: €900,000.00
Bonus: --
Antoine Flochel
Vice Chairman of the Board, Since 2005
Salary: €160,000.00
Bonus: --
Aymeric le Chatelier
Executive Vice President - Finance, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

65, quai Georges Gorse
BOULOGNE-BILLANCOURT     92100

Phone: +331.58335000

Ipsen SA is a France-based pharmaceutical company. The Company is focused on various therapeutic areas, including onocology, endocrinology, neurosciences and primary care. Its onocology portfolio includes Somatuline, Decapeptyl, Hexvix and Cabometyx. Its endocrinology portfolio includes Increlex and NutropinAq. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, Tanakan and Adenuric. The Company is also engaged in the clinical development program for ONIVYDE, which is an encapsulated formulation of irinotecan. ONIVYDE is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company operates two technological platforms, which includes toxins and peptides. It also operates three research and development centers located in France, United Kingdom and United States.

SPONSORED STORIES